422 related articles for article (PubMed ID: 24456319)
1. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
2. Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Manag Care Spec Pharm; 2015 Oct; 21(10):965-72. PubMed ID: 26402395
[TBL] [Abstract][Full Text] [Related]
3. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
5. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
6. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
LaMori JC; Shoheiber O; Mody SH; Bookhart BK
Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
[TBL] [Abstract][Full Text] [Related]
7. Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.
Lang K; Patel AA; Munsell M; Bookhart BK; Mody SH; Schein JR; Menzin J
J Thromb Thrombolysis; 2015 May; 39(4):434-42. PubMed ID: 25079971
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.
Casciano JP; Dotiwala Z; Kemp R; Li C; Cai J; Preblick R
Am J Health Syst Pharm; 2015 Feb; 72(4):291-300. PubMed ID: 25631836
[TBL] [Abstract][Full Text] [Related]
9. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
10. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
[TBL] [Abstract][Full Text] [Related]
11. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
[No Abstract] [Full Text] [Related]
12. Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
Spyropoulos AC; Preblick R; Kwong WJ; Lingohr-Smith M; Lin J
Clin Appl Thromb Hemost; 2017 Sep; 23(6):532-541. PubMed ID: 27899520
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
14. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
[No Abstract] [Full Text] [Related]
16. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
[TBL] [Abstract][Full Text] [Related]
17. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
Spyropoulos AC; Lin J
J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
[TBL] [Abstract][Full Text] [Related]
18. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
[TBL] [Abstract][Full Text] [Related]
19. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
20. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
